Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
2423
mi
from 98109
Springfield, MA
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
2423
mi
from 98109
Springfield, MA
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
872
mi
from 98109
Las Vegas, NV
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
872
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
2418
mi
from 98109
Garden City, NY
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
2418
mi
from 98109
Garden City, NY
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
1889
mi
from 98109
Bellaire, TX
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
1889
mi
from 98109
Bellaire, TX
Click here to add this to my saved trials
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated:  11/18/2015
Research Site
5390
mi
from 98109
Cordoba,
Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities
Status: Enrolling
Updated: 11/18/2015
Research Site
5390
mi
from 98109
Cordoba,
Click here to add this to my saved trials
Quantitative MR Biomarkers for Sarcoma Treatment
Quantitative MR Biomarkers for Sarcoma Treatment
Status: Enrolling
Updated:  12/2/2015
University of Michigan Health System
1903
mi
from 98109
Ann Arbor, MI
Quantitative MR Biomarkers for Sarcoma Treatment
Quantitative MR Biomarkers for Sarcoma Treatment
Status: Enrolling
Updated: 12/2/2015
University of Michigan Health System
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Scleroderma ARFI Imaging of the Skin
Acoustic Radiation Force Impulse/Shear Wave Velocity Imaging of the Skin in Scleroderma and Other Rheumatologic Diseases
Status: Enrolling
Updated:  12/7/2015
University of Michigan Hospital
1905
mi
from 98109
Ann Arbor, MI
Scleroderma ARFI Imaging of the Skin
Acoustic Radiation Force Impulse/Shear Wave Velocity Imaging of the Skin in Scleroderma and Other Rheumatologic Diseases
Status: Enrolling
Updated: 12/7/2015
University of Michigan Hospital
1905
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)
Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate
Status: Enrolling
Updated:  12/14/2015
Central Arkansas Veterans Healthcare System
1779
mi
from 98109
Little Rock, AR
Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)
Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate
Status: Enrolling
Updated: 12/14/2015
Central Arkansas Veterans Healthcare System
1779
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
Study of a Bradykinin Receptor Blocker in Angiotensin Converting Enzyme Inhibitor-Associated Angioedema
Status: Enrolling
Updated:  12/16/2015
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
Study of a Bradykinin Receptor Blocker in Angiotensin Converting Enzyme Inhibitor-Associated Angioedema
Status: Enrolling
Updated: 12/16/2015
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.
Status: Enrolling
Updated:  12/17/2015
Johns Hopkins Arthritis Center
2331
mi
from 98109
Baltimore, MD
Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.
Status: Enrolling
Updated: 12/17/2015
Johns Hopkins Arthritis Center
2331
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Status: Enrolling
Updated:  12/17/2015
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Status: Enrolling
Updated: 12/17/2015
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated:  12/31/2015
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated: 12/31/2015
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated:  12/31/2015
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated: 12/31/2015
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated:  12/31/2015
Walter Reed National Military Medical Center (WRNMMC)
2316
mi
from 98109
Bethesda, MD
Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury
Status: Enrolling
Updated: 12/31/2015
Walter Reed National Military Medical Center (WRNMMC)
2316
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury (Coordinating Center Protocol)
Status: Enrolling
Updated:  1/2/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center
Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury (Coordinating Center Protocol)
Status: Enrolling
Updated: 1/2/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated:  1/7/2016
North Shore LIJ Medical Center
2412
mi
from 98109
Great Neck, NY
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated: 1/7/2016
North Shore LIJ Medical Center
2412
mi
from 98109
Great Neck, NY
Click here to add this to my saved trials
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated:  1/7/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis
Status: Enrolling
Updated: 1/7/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated:  1/13/2016
John Muir Clinical Research Center
667
mi
from 98109
Concord, CA
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated: 1/13/2016
John Muir Clinical Research Center
667
mi
from 98109
Concord, CA
Click here to add this to my saved trials
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated:  1/13/2016
Royal Hobart Hospital
8316
mi
from 98109
Hobart,
Hyperbaric Oxygen in Lower Leg Trauma
Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.
Status: Enrolling
Updated: 1/13/2016
Royal Hobart Hospital
8316
mi
from 98109
Hobart,
Click here to add this to my saved trials
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated:  1/20/2016
Houston Medical Center Building
1892
mi
from 98109
Houston, TX
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
Status: Enrolling
Updated: 1/20/2016
Houston Medical Center Building
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Status: Enrolling
Updated:  1/21/2016
NYU Medical Center
2402
mi
from 98109
New York, NY
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
Status: Enrolling
Updated: 1/21/2016
NYU Medical Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Trial on Wheeled Mobility for Preventing Pressure Ulcers
RCT on Wheeled Mobility for Preventing Pressure Ulcers
Status: Enrolling
Updated:  1/25/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Trial on Wheeled Mobility for Preventing Pressure Ulcers
RCT on Wheeled Mobility for Preventing Pressure Ulcers
Status: Enrolling
Updated: 1/25/2016
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
1072
mi
from 98109
Chula Vista, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
1072
mi
from 98109
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
1063
mi
from 98109
La Mesa, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
1063
mi
from 98109
La Mesa, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
1031
mi
from 98109
Oceanside, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
1031
mi
from 98109
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
942
mi
from 98109
Oxnard, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
942
mi
from 98109
Oxnard, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
956
mi
from 98109
Pasadena, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
956
mi
from 98109
Pasadena, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
987
mi
from 98109
Santa Ana, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
987
mi
from 98109
Santa Ana, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
975
mi
from 98109
Torrance, CA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
975
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
2207
mi
from 98109
Columbus, GA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
2207
mi
from 98109
Columbus, GA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
2404
mi
from 98109
Savannah, GA
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
2404
mi
from 98109
Savannah, GA
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
1704
mi
from 98109
Springfield, IL
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
1704
mi
from 98109
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
477
mi
from 98109
Butte, MT
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
477
mi
from 98109
Butte, MT
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
2421
mi
from 98109
Somers Point, NJ
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
2421
mi
from 98109
Somers Point, NJ
Click here to add this to my saved trials
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated:  1/26/2016
Clinical Research Facility
2041
mi
from 98109
Akron, OH
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Status: Enrolling
Updated: 1/26/2016
Clinical Research Facility
2041
mi
from 98109
Akron, OH
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
1117
mi
from 98109
Scottsdale, AZ
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
1117
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
944
mi
from 98109
Granada Hills, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
944
mi
from 98109
Granada Hills, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
671
mi
from 98109
Walnut Creek, CA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
671
mi
from 98109
Walnut Creek, CA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
1070
mi
from 98109
Colorado Springs, CO
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
1070
mi
from 98109
Colorado Springs, CO
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
1821
mi
from 98109
Shreveport, LA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
1821
mi
from 98109
Shreveport, LA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
2316
mi
from 98109
Chevy Chase, MD
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
2316
mi
from 98109
Chevy Chase, MD
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
2485
mi
from 98109
Boston, MA
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
1380
mi
from 98109
Plymouth, MN
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
1380
mi
from 98109
Plymouth, MN
Click here to add this to my saved trials
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated:  2/15/2016
Clinical Research Facility
1720
mi
from 98109
St Louis, MO
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Status: Enrolling
Updated: 2/15/2016
Clinical Research Facility
1720
mi
from 98109
St Louis, MO
Click here to add this to my saved trials